HJB97 is a high-affinity BET inhibitor with K i s of 0.9 nM ( BRD2 BD1 ), 0.27 nM ( BRD2 BD2 ), 0.18 nM ( BRD3 BD1 ), 0.21 nM ( BRD3 BD2 ), 0.5 nM ( BRD4 BD1 ), 1.0 nM ( BRD4 BD2 ), respectively. HJB97 is employed for the design of potential PROTAC BET d
Storage Temp
Store at -20°C
Shipped In
Ice chest + Ice pads
Product Description
HJB97 is a high-affinity BET inhibitor with K i s of 0.9 nM ( BRD2 BD1 ), 0.27 nM ( BRD2 BD2 ), 0.18 nM ( BRD3 BD1 ), 0.21 nM ( BRD3 BD2 ), 0.5 nM ( BRD4 BD1 ), 1.0 nM ( BRD4 BD2 ), respectively. HJB97 is employed for the design of potential PROTAC BET degrader and has antitumor activity
In Vitro
HJB97 is a highly potent and efficacious bomodomain and extra terminal (BET) inhibitor with IC 50 s of 3.1 nM (BRD2 BD1), 3.9 nM (BRD2 BD2), 6.6 nM (BRD3 BD1), 1.9 nM (BRD3 BD2), 7.0 nM (BRD4 BD1), 7.0 nM (BRD4 BD2). HJB97 (10-1000 nM, 4 days) potently inhibits cell growth in RS4;11 and MOLM-13 acute leukemia cell lines with IC 50 s of 24.1 nM and 25.6 nM. HJB97 can effectively down-regulate the level of c-Myc at concentrations of 300-1000 nM in the RS4;11 cell line (treated for 24 h). MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: The human acute leukemia RS4;11 cell line; The human acute leukemia MOLM-13 cell line Concentration: 10-1000 nM Incubation Time: 4 days Result: Achieved IC 50 s value of 24.1±5.3 nM and 25.6±1.9 nM in inhibition of the RS4;11 cell and MOLM-13 cell growth. Western Blot AnalysisCell Line: RS4;11 cells Concentration: 30, 100, 300, 1000 nM Incubation Time: 24 h Result: Down-regulated the level of c-Myc but at concentrations of 300-1000 nM in the RS4;11 cell line.
